UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Normative Data for the NeuroCom Sensory Organization Test in United States Military Academy Boxers

International journal of sports physical therapy, 2022-01, Vol.17 (3), p.366-377

2022

Volltextzugriff (PDF)

Long-term efficacy of pregabalin in generalized anxiety disorder

International clinical psychopharmacology, 2008-01, Vol.23 (1), p.18-28

2008

Volltextzugriff (PDF)

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study

International clinical psychopharmacology, 2011-09, Vol.26 (5), p.243-251

2011

Volltextzugriff (PDF)

A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam

Human psychopharmacology, 2005-06, Vol.20 (4), p.263-273

2005

Volltextzugriff (PDF)

The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit-Risk Assessment

Clinical pharmacology and therapeutics, 2009-03, Vol.85 (3), p.277-282

2009

Volltextzugriff (PDF)

Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study

International clinical psychopharmacology, 2011-07, Vol.26 (4), p.213-220

2011

Volltextzugriff (PDF)

Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial

The American journal of psychiatry, 2003-03, Vol.160 (3), p.533-540

2003

Volltextzugriff (PDF)

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

Journal of clinical psychopharmacology, 2005-04, Vol.25 (2), p.151-158

2005

Volltextzugriff (PDF)

P.4.a.008 Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder

European neuropsychopharmacology, 2010, Vol.20, p.S525-S525

2010

Volltextzugriff (PDF)

P.4.a.009 Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo-controlled, fixed-dose study

European neuropsychopharmacology, 2010, Vol.20, p.S525-S526

2010

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder

Journal of clinical psychopharmacology, 2003-06, Vol.23 (3), p.240

2003

Volltextzugriff (PDF)

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

Journal of clinical psychopharmacology, 2004-04, Vol.24 (2), p.141-149

2004

Volltextzugriff (PDF)

P.358The value of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): improved survival, pulmonary and nutritional support, and motor function with decreased hospitalization

Neuromuscular disorders : NMD, 2019-10, Vol.29, p.S186-S186

2019

Volltextzugriff (PDF)

SMA – THERAPY

Neuromuscular disorders : NMD, 2020-10, Vol.30, p.S123

2020

Volltextzugriff (PDF)

SMA – THERAPY: P.262 Value of onasemnogene abeparvovec in spinal muscular atrophy type 1: improvements in motor function, ventilation-free survival, and hospitalizations

Neuromuscular disorders : NMD, 2020-10, Vol.30, p.S123-S123

2020

Volltextzugriff (PDF)

SMA THERAPIES I

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S83

2018

Volltextzugriff (PDF)

SMA THERAPIES I: P.182Early diagnosis and speed to effect in infant-onset spinal muscular atrophy

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S83-S83

2018

Volltextzugriff (PDF)

P.357Type I spinal muscular atrophy patients treated with AVXS-101 have greater health outcome improvements and lower use of ventilatory support, hospitalization, and associated costs contrasted to those treated with nusinersen

Neuromuscular disorders : NMD, 2019-10, Vol.29, p.S185-S186

2019

Volltextzugriff (PDF)

P.209Event-free survival and motor milestone achievement following onasemnogene abeparvovec and nusinersen interventions contrasted to natural history for spinal muscular atrophy t1 (SMA1) patients

Neuromuscular disorders : NMD, 2019-10, Vol.29, p.S127-S127

2019

Volltextzugriff (PDF)

PSY18 - RAPID IMPROVEMENTS IN MOTOR FUNCTION IN SPINAL MUSCULAR ATROPHY TYPE 1 FOLLOWING AVXS-101 GENE REPLACEMENT THERAPY

Value in health, 2018-10, Vol.21, p.S438-S439

2018

Volltextzugriff (PDF)

SMA – THERAPY: P.256 Intravenous (IV) onasemnogene abeparvovec for spinal muscular atrophy (SMA): integrated safety report

Neuromuscular disorders : NMD, 2020-10, Vol.30, p.S120-S121

2020

Volltextzugriff (PDF)

SMA – THERAPY

Neuromuscular disorders : NMD, 2020-10, Vol.30, p.S120-S121

2020

Volltextzugriff (PDF)

PND11 - INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY

Value in health, 2018-10, Vol.21, p.S330-S331

2018

Volltextzugriff (PDF)

How modeling and simulation have enhanced decision making in new drug development

Journal of pharmacokinetics and pharmacodynamics, 2005-04, Vol.32 (2), p.185-197

2005

Volltextzugriff (PDF)

Feasibility of assessing differential pharmacodynamic (PD)/adverse events (AE) profiles on CNS agents

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P27-P27

2005

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(91)

Publikationsform

Artikel
(115)
Texte
(2)
Buchkapitel
(1)
Berichte
(1)

Sprache

Englisch
(117)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Life Sciences & Biomedicine
(46)
Humans
(35)
Female
(29)
Male
(28)
Biological And Medical Sciences
(24)
Psychiatry
(18)
Adult
(16)
Medical Sciences
(16)
Double-Blind Method
(14)
Pharmacology & Pharmacy
(14)
Pharmacology. Drug Treatments
(14)
Animals
(12)
Psychology. Psychoanalysis. Psychiatry
(12)
Neuropharmacology
(11)
Gamma-Aminobutyric Acid - Analogs & Derivatives
(9)
Infant, Newborn
(9)
Middle Aged
(9)
Neuromuscular Diseases
(9)
Pregabalin
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Normative Data for the NeuroCom Sensory Organization Test in United States Military Academy Boxers

Long-term efficacy of pregabalin in generalized anxiety disorder

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study

A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam

The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit-Risk Assessment

Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study

Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

P.4.a.008 Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder

P.4.a.009 Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo-controlled, fixed-dose study

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

P.358The value of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): improved survival, pulmonary and nutritional support, and motor function with decreased hospitalization

SMA – THERAPY

SMA – THERAPY: P.262 Value of onasemnogene abeparvovec in spinal muscular atrophy type 1: improvements in motor function, ventilation-free survival, and hospitalizations

SMA THERAPIES I

SMA THERAPIES I: P.182Early diagnosis and speed to effect in infant-onset spinal muscular atrophy

P.357Type I spinal muscular atrophy patients treated with AVXS-101 have greater health outcome improvements and lower use of ventilatory support, hospitalization, and associated costs contrasted to those treated with nusinersen

P.209Event-free survival and motor milestone achievement following onasemnogene abeparvovec and nusinersen interventions contrasted to natural history for spinal muscular atrophy t1 (SMA1) patients

PSY18 - RAPID IMPROVEMENTS IN MOTOR FUNCTION IN SPINAL MUSCULAR ATROPHY TYPE 1 FOLLOWING AVXS-101 GENE REPLACEMENT THERAPY

SMA – THERAPY: P.256 Intravenous (IV) onasemnogene abeparvovec for spinal muscular atrophy (SMA): integrated safety report

SMA – THERAPY

PND11 - INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY

How modeling and simulation have enhanced decision making in new drug development

Feasibility of assessing differential pharmacodynamic (PD)/adverse events (AE) profiles on CNS agents

Suchergebnisse filtern